Evading and overcoming AAV neutralization in gene therapy.

Area of Science:

• Gene therapy
• Immunology
• Viral vectors

Background:

• Adeno-associated virus (AAV) vectors are key for treating monogenic disorders.
• Over 250 AAV-based clinical trials are underway globally.
• Pre-existing immunity and potential re-administration challenges limit AAV therapy reach.

Purpose of the Study:

• To review current technologies for evading AAV-induced immune responses.
• To explore strategies for overcoming immunity to AAV gene therapies.
• To discuss prospects for enabling AAV therapy re-administration.

Main Methods:

• Review of existing literature on AAV immunology.
• Analysis of current strategies for immune evasion.
• Discussion of future technological developments.

Main Results:

• Several technologies are emerging to manage pre-existing immunity.
• Methods to allow AAV vector re-administration are under development.
• These advancements aim to broaden patient access to gene therapies.

Conclusions:

• Overcoming immune barriers is essential for maximizing AAV therapy impact.
• Further research into immune modulation and vector design is critical.
• These strategies will expand the applicability of AAV gene therapies for genetic diseases.